Monthly report from the EU Pharmacovigilance Risk Assessment Committee (PRAC) - November 2014

14 November 2014

The EU Pharmacovigilance Risk Assessment Committee (PRAC) convened on 3-6 November 2014. Topics discussed at the meeting:

  • PRAC recommends measures to reduce risk of heart problems with Corlentor/Procoralan (ivabradine)
  • PRAC recommends further assessment of risk of developing inhibitors with Kogenate Bayer/Helixate NexGen
  • PRAC advises informing about first case of PML in a patient treated with Tecfidera

Read PRAC's monthly report from the meeting 3-6 November 2014

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.